1. “Pfizer ends research for new Alzheimer’s, Parkinson’s drugs” https://www.reuters.com/article/us-pfizer-alzheimers/pfizer-ends-research-for-new-alzheimers-parkinsons-drugs-idUSKBN1EW0TN Accessed Feb 8, 2018.
2. Prince M, Wilmo A, Guerchet M, Ali G, Wu Y, Prina M. World Alzheimer Report 2015: The global impact of dementia: an analysis of prevalence, incidence, cost and trends. Alzheimer’s Disease International. 2015. http://www.alz.co.uk/research/world-report-2015 Accessed Feb 8, 2018.
3. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer’s disease;RS Doody;N Engl J Med,2014
4. Trial of Solanezumab for Mild Dementia Due to Alzheimer’s Disease;L Honig;N Engl J Med,2018
5. Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer’s disease: a randomised, controlled, double-blind, parallel-arm, phase 3 trial;S Gauthier;Lancet,2016